

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

## How to get the most out of a discussion with your doctor about **KEYTRUDA**

What to ask and how to start a conversation about **KEYTRUDA** for high-risk early-stage triple-negative breast cancer (TNBC)



KEYTRUDA is a prescription medicine used to treat a kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines as treatment before surgery and then continued alone after surgery when you have early-stage breast cancer, **and** are at high risk of your breast cancer coming back.

### Important Safety Information

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen any time during treatment or even after your treatment has ended.

**See additional Important Safety Information on pages 4-9.**

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 4-9.

## Your questions matter in treatment discussions with your doctor



Actor Portrayal

During your treatment conversations, it's important to voice any questions you might have. Here are some questions you can use when talking through treatment with KEYTRUDA:

- Can KEYTRUDA be part of my treatment plan?
- How does KEYTRUDA work?
- How soon should I start treatment?
- Will I need treatment before and after surgery?
- Is there a chance my cancer may return after surgery?
- What are my treatment options if I'm at risk of my cancer returning?
- What are the potential risks and benefits of KEYTRUDA?

When it comes to treatment for high-risk early-stage TNBC, it may feel overwhelming to have to make important decisions about your care. But know that **you're not alone**. Your doctor understands that this might be all new information to you and is ready to answer any questions you may have. Remember, **your voice matters** during treatment discussions.



It can be helpful to take notes during the conversation. If you have someone that can come to the appointment with you, they can serve as an extra listening ear and take notes for you.

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1 and 4-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

## Understanding what your care team can do for you



Your care team is made up of many different professionals working together to support you before, during, and after treatment. Here are some questions you can ask your oncologist or nurse about your care team:

- Who are the members of my care team?
- Who can I speak to about my emotional and mental well-being?
- Who can I speak to if I have questions about finances, transportation, insurance, or treatment costs?
- Who can I speak to about managing the common side effects of cancer treatment and my day-to-day health after treatment?
- Who can I speak to for nutritional advice after treatment?



Visit [keytruda.com/careteam](https://keytruda.com/careteam) to learn more about your care team and for tips during treatment

Please read the accompanying **Medication Guide** for KEYTRUDA and discuss it with your doctor. The physician **Prescribing Information** also is available. You can find additional **Important Safety Information** about KEYTRUDA on pages 1 and 4-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg





## Important Safety Information (*continued*)

Call or see your health care provider right away if you develop any signs or symptoms of the following problems or if they get worse. These are not all of the signs and symptoms of immune system problems that can happen with KEYTRUDA:

### Lung problems:

- Cough
- Shortness of breath
- Chest pain

### Intestinal problems:

- Diarrhea (loose stools) or more frequent bowel movements than usual
- Stools that are black, tarry, sticky, or have blood or mucus
- Severe stomach-area (abdomen) pain or tenderness

### Liver problems:

- Yellowing of your skin or the whites of your eyes
- Severe nausea or vomiting
- Pain on the right side of your stomach area (abdomen)
- Dark urine (tea colored)
- Bleeding or bruising more easily than normal

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1 and 5-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg



# Important Safety Information (*continued*)

## Hormone gland problems:

- Headaches that will not go away or unusual headaches
- Eye sensitivity to light
- Eye problems
- Rapid heartbeat
- Increased sweating
- Extreme tiredness
- Weight gain or weight loss
- Feeling more hungry or thirsty than usual
- Urinating more often than usual
- Hair loss
- Feeling cold
- Constipation
- Your voice gets deeper
- Dizziness or fainting
- Changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

## Kidney problems:

- Decrease in your amount of urine
- Blood in your urine
- Swelling of your ankles
- Loss of appetite

## Skin problems:

- Rash
- Itching
- Skin blistering or peeling
- Painful sores or ulcers in your mouth or in your nose, throat, or genital area
- Fever or flu-like symptoms
- Swollen lymph nodes

Please read the accompanying **Medication Guide** for KEYTRUDA and discuss it with your doctor. The physician **Prescribing Information** also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1, 4, and 6-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

## Important Safety Information (*continued*)

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with KEYTRUDA. Call or see your health care provider right away for any new or worsening signs or symptoms, which may include:

- Chest pain, irregular heartbeat, shortness of breath, swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

- Chills or shaking
- Itching or rash
- Flushing
- Shortness of breath or wheezing
- Dizziness
- Feeling like passing out
- Fever
- Back pain

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1, 4, 5, and 7-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

## Important Safety Information (*continued*)



Actor Portrayal

**Rejection of a transplanted organ or tissue.** Your health care provider should tell you what signs and symptoms you should report and they will monitor you, depending on the type of organ or tissue transplant that you have had.

**Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).** These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your health care provider will monitor you for these complications.

**Getting medical treatment right away may help keep these problems from becoming more serious.** Your health care provider will check you for these problems during treatment with KEYTRUDA. They may treat you with corticosteroid or hormone replacement medicines. They may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1, 4-6, 8, and 9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg



## Important Safety Information (*continued*)

**Before you receive KEYTRUDA, tell your health care provider if you** have immune system problems such as Crohn's disease, ulcerative colitis, or lupus; have had an organ or tissue transplant, including corneal transplant, or have had or plan to have a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic); have had radiation treatment in your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

If you are pregnant or plan to become pregnant, tell your health care provider. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, you will be given a pregnancy test before you start treatment. Use effective birth control during treatment with KEYTRUDA and for 4 months after your last dose of KEYTRUDA. Tell them right away if you think you may be pregnant or you become pregnant during treatment with KEYTRUDA.

Tell your health care provider if you are breastfeeding or plan to breastfeed. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your last dose of KEYTRUDA.

**Tell your health care provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**Common side effects of KEYTRUDA when used alone include** feeling tired; pain, including pain in muscles; rash; diarrhea; fever; cough; decreased appetite; itching; shortness of breath; constipation; bones or joints and stomach-area (abdominal) pain; nausea; and low levels of thyroid hormone.

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1, 4-7, and 9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

## Important Safety Information (*continued*)

**Common side effects of KEYTRUDA when given with certain chemotherapy or chemotherapy with radiation therapy medicines** include feeling tired or weak; nausea; constipation; diarrhea; decreased appetite; rash; vomiting; cough; trouble breathing; fever; hair loss; inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs; swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; mouth sores; headache; weight loss; stomach-area (abdominal) pain; joint and muscle pain; trouble sleeping; blisters or rash on the palms of your hands and soles of your feet; urinary tract infection; low levels of thyroid hormone; skin irritation in the radiation area; trouble swallowing; and dry mouth.

These are not all the possible side effects of KEYTRUDA. Talk to your health care provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.



Please read the accompanying **Medication Guide** for KEYTRUDA and discuss it with your doctor. The physician **Prescribing Information** also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1 and 4-8.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

# Exploring a treatment plan with **KEYTRUDA**

For people with high-risk early-stage TNBC, a treatment plan includes KEYTRUDA + chemotherapy before surgery, and KEYTRUDA alone after surgery.

- ▶ **A diagnosis of high-risk early-stage triple-negative breast cancer means there may be a higher chance of the cancer returning after surgery.** It's important to work with your doctors and ask questions to learn whether treatment with KEYTRUDA before and after surgery is right for you.
- ▶ **You may hear terms like “neoadjuvant treatment” or “adjuvant treatment.”** Neoadjuvant treatment refers to treatment before surgery, while adjuvant treatment refers to treatment after surgery. These phrases may come up when discussing treatment with KEYTRUDA.



Begin treatment with  
**KEYTRUDA + chemotherapy**

**KEYTRUDA**

**Chemotherapy**

**Surgery**



Continue treatment  
with **KEYTRUDA alone**

**KEYTRUDA**



## Why **KEYTRUDA** before and after surgery?

Scan the QR code or visit [keytruda.com/TNBCresults](https://keytruda.com/TNBCresults) to learn more about clinical trial results with KEYTRUDA

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1 and 4-9.

**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg



**KEYTRUDA**<sup>®</sup>  
(pembrolizumab) Injection 100 mg

**Ask your doctor about  
a treatment plan with  
KEYTRUDA at your  
appointment**

Actor Portrayal



Scan the QR code or [visit keytruda.com](https://www.keytruda.com)  
to learn more about KEYTRUDA

Please read the accompanying [Medication Guide](#) for KEYTRUDA and discuss it with your doctor. The physician [Prescribing Information](#) also is available. You can find additional Important Safety Information about KEYTRUDA on pages 1 and 4-9.

Copyright © 2025 Merck & Co., Inc., Rahway, NJ,  
USA and its affiliates. All rights reserved.  
US-OBR-02618 07/25

